F&P reports ‘strong’ first half

AUCKLAND, New Zealand – Fisher & Paykel Healthcare has provided guidance for the first half of the 2026 financial year, which ends September 2025. 
   
At July 31 exchange rates, guidance assumptions for the first half of the 2026 financial year include a continuation of the current trading environment and result in revenue of approximately $1.075 billion and net profit after tax of approximately $200 million. This would equate to approximately 13% growth in reported operating revenue and approximately 31% growth in reported net profit after tax, compared to the first half of the 2025 financial year. 
 
“We had a very strong first half last year across both Homecare and Hospital product groups, with 17% revenue growth in constant currency,” said Lewis Gradon, managing director and CEO. “Against that backdrop, an ongoing change in clinical practice to our Hospital therapies continues to contribute to our outlook for strong growth for the first half of this year.” 
 
Outlook for the 2026 financial year 
 
The company’s outlook for the full year remains unchanged, with operating revenue in the range of approximately $2.15 billion to $2.25 billion and net profit after tax in the range of approximately $390 million to $440 million. 
 
This outlook now includes an estimated 75-basis point impact of US tariffs on hospital products sourced from New Zealand. It also assumes current global tariff rates, policies and applications for the duration of this financial year. 
 
Board director Pip Greenwood to retire 
 
Director Pip Greenwood has announced her intention to retire from the board of Fisher & Paykel Healthcare, effective Sept. 1, 2025. Greenwood has served as an independent director of Fisher & Paykel Healthcare since June 2017.